Ayble Health, based in Boston, MA, has announced a Series A funding round of $16 million led by Neon Fund and other participants like Unum Ventures, M13, Upfront Ventures, DigiTx Partners, and Cleveland Clinic Ventures, along with other strategic angel investors. With this funding, the total amount raised by the company so far has reached $27M.
Ayble Health is a company that uses AI precision tools to provide virtual multidisciplinary digestive care and is backed by 16+ peer-reviewed studies that are published in major international institutions like Cleveland Clinic. The company plans to use this funding to extend its core clinical model into closely linked, adjacent therapeutic areas that focuses first on comprehensive autoimmune health. It will also use this funding to deepen AI-Clinician Personalization as well as Expanding Enterprise Accessibility. The company plans to collaborate with patients, providers, enterprise clients, and institutional investors to define the gold standard for specialty virtual care.
Sam Jactel is the Founder & CEO of Ayble Health, while Melissa Ackerman serves as Commercial Strategy Leader, Trent Haywood as Clinical Director, Nina Montgomery as Head of Product, Aidan Barrow as Vice President of Operations, and Maryann Watson as Marketing Head, along with many other Clinical advisors.
Company Name: Ayble Health
Year Founded: 2020
Headquarters Location: Boston, MA
Founder Names: Sam Jactel (Founder & CEO)
Investment Secured: $16 Million (Series A Round)
Investing Firms: Neon Fund (lead investor), Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx Partners, and strategic backing from angel investors
